Pharma giant Pfizer recently announced a $350 million partnership with Biocon, one of Asia’s leading biotechnology companies. The deal gives Pfizer the exclusive rights to commercialize Biocon’s biosimilar versions of insulin. (For full disclosure: Dr. Prasad Kaipa, one of the authors, headed up the Biocon Cell for Innovation Management at the Indian School of Business till April 2010)